JOURNAL ARTICLE

New Psychosis Findings from University of Oxford Outlined (Antipsychotic drugs at 75: the past, present, and future of psychosis management).

  • Published In: Mental Health Weekly Digest, 2025. P. 1880 1 of 2

  • Database: Psychology Source 2 of 2

Abstract

The article focuses on the evolution of antipsychotic treatments for psychosis, particularly in the context of schizophrenia, marking the 75th anniversary of chlorpromazine's introduction. Research from the University of Oxford highlights that while antipsychotics effectively reduce positive symptoms, their impact on negative and cognitive symptoms remains limited. The study emphasizes the need for further exploration of nondopaminergic treatments, such as xanomeline-trospium, and advocates for refined treatment approaches and the integration of precision psychiatry in managing psychosis. Financial support for the research was provided by organizations including the NIHR Oxford Health Biomedical Research Centre and the Wellcome Trust. [Extracted from the article]

Additional Information

  • Source:Mental Health Weekly Digest. 2025/10, p1880
  • Document Type:Article
  • Subject Area:Pharmacy and Pharmacology
  • Publication Date:2025
  • ISSN:1543-6616
  • Accession Number:188743719
  • Copyright Statement:Copyright of Mental Health Weekly Digest is the property of NewsRx and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.